Hepatitis C virus (HCV) RNA clearance rates
| HCV RNA clearance rates by PCR | ||||||
|---|---|---|---|---|---|---|
| Intention to treat analysis (n = 171) | Response among those who completed 24 weeks of therapy (n = 136) | |||||
| Amantadine | Placebo | p Value | Amantadine | Placebo | p Value | |
| PCR, polymerase chain reaction; SVR, sustained viral response; ETR, end of treatment response. | ||||||
| 24 wks during treatment | 40.0% (n = 34) | 45.3% (n = 39) | 0.3 | 49.3% (n = 34) | 56.5% (n = 39) | 0.2 |
| ETR at 48 wks | 32.9% (n = 28) | 38.4% (n = 33) | 0.3 | 40.6% (n = 28) | 47.8% (n = 33) | 0.2 |
| SVR at 24 wks post-treatment | 24.7% (n = 21) | 27.9% (n = 24) | 0.4 | 30.4% (n = 21) | 34.8% (n = 24) | 0.4 |